✦ LIBER ✦

In vitro characteristics of highly purified factor VIII concentrates

✍ Scribed by Massimo Morfini

Publisher: Springer
Year: 1991
Tongue: English
Weight: 249 KB
Volume: 63
Category: Article
ISSN: 0939-5555
DOI: 10.1007/bf01703241

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of highly purified fact

Characterization of highly purified factor VIII products

✍ H. Beeser 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 321 KB

In vitro reactivity of factor VIII inhib

In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates

✍ Giuseppe Tagariello; Daniela Zanotto; Paolo Radossi; Roberto Sartori; Donata Bel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

Reduced serum haptoglobin values in hemo

Reduced serum haptoglobin values in hemophiliacs receiving monoclonally purified factor viii concentrates

✍ George R. Buchanan; Christine A. Holtkamp; Andrea Johnson 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB 👁 2 views

Continuous infusion of highly purified f

Continuous infusion of highly purified factor VIII (monoclate M)

✍ Sanjeet Flora; Henry Hambley; Jill Thumpston; Jane Clark 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

In vitro characterization of commercial

In vitro characterization of commercial factor VIII concentrates: Long-term follow-up

✍ Miyashita, C. ;Hellstern, P. ;K�hler, M. ;Blohn, G. ;Wenzel, E. 📂 Article 📅 1984 🏛 Springer-Verlag ⚖ 378 KB

Fifty batches of Factor VIII concentrates from 12 producers were characterized in a long-term follow-up. The following parameters were measured: Factor VIII: C, Factor VIIIR: AG, Factor VIII: Rcof, specific activity (U Factor VIII: C/mg protein), fibrinogen, IgG, IgM, IgA, isoagglutinins, Hbs-AG, he

Viral safety of a new highly purified fa

Viral safety of a new highly purified factor VIII (OCTATE)

✍ Biesert, Lothar; Lemon, Stanley; Goudeau, Alain; Suhartono, Haryadi; Wang, Lingr 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 666 KB

The inactivation of both transfusion-relevant and model viruses by modified pasteurisation (10 hours at 63°C in solution) has been evaluated following the established guidelines of the EU CPMP Ad Hoc Working Party on Biotechnology/ Pharmacy. This heat treatment was introduced into the manufacturing